Ticagrelor NDC 69452-509

NDC codes

FDA NDC Directory

Product NDC (as listed)69452-509Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69452-0509Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69452-509-17	69452050917	60 TABLET in 1 BOTTLE (69452-509-17)Marketed from Oct 28, 2025
69452-509-30	69452050930	500 TABLET in 1 BOTTLE (69452-509-30)Marketed from Oct 28, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ticagrelor
Generic name (nonproprietary): ticagrelor
Active ingredients: Ticagrelor — 90 mg/1
Dosage form: Tablet
Route: Oral
Labeler: BIONPHARMA INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216187
Marketing start: Oct 28, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P-Glycoprotein Inhibitors (Mechanism)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 69452-509_4239fd4a-d16e-1e86-e063-6294a90a4406SPL ID 4239fd4a-d16e-1e86-e063-6294a90a4406SPL set ID 4239fc4c-dae6-eb51-e063-6394a90a00d5RxCUI 1116635, 1666332UNII GLH0314RVCUPC 0369452508305, 0369452509302, 0369452509173, 0369452508176
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469452050917 followed by a unit qualifier and the quantity

Package 69452-0509-17. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 28, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of st…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 216187

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216187
Product	Strength	Form · route	Labeler	Product NDC
Ticagrelor	Ticagrelor 60 mg/1	TabletOral	BIONPHARMA INC.	69452-508
Ticagrelor	Ticagrelor 90 mg/1	TabletOral	Changzhou Pharmaceutical Factory	55488-0543
Ticagrelor	Ticagrelor 60 mg/1	TabletOral	Changzhou Pharmaceutical Factory	55488-0544